Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alto Neuroscience (ANRO) Equity Ratio (2023 - 2026)

Alto Neuroscience has reported Equity Ratio over the past 4 years, most recently at 0.88 for Q1 2026.

  • Quarterly results put Equity Ratio at 0.88 for Q1 2026, up 8.88% from a year ago — trailing twelve months through Mar 2026 was 0.88 (up 8.88% YoY), and the annual figure for FY2025 was 0.82, down 4.07%.
  • Equity Ratio reached 0.88 in Q1 2026 per ANRO's latest filing, up from 0.82 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q1 2024 and bottomed at 0.83 in Q4 2023.
  • Median Equity Ratio over the past 4 years was 0.84 (2024), compared with a mean of 0.68.
  • The largest annual shift saw Equity Ratio skyrocketed 203.11% in 2024 before it dropped 14.18% in 2025.
  • Over 4 years, Equity Ratio stood at 0.83 in 2023, then skyrocketed by 203.11% to 0.85 in 2024, then decreased by 4.07% to 0.82 in 2025, then increased by 7.65% to 0.88 in 2026.
  • Business Quant data shows Equity Ratio for ANRO at 0.88 in Q1 2026, 0.82 in Q4 2025, and 0.76 in Q3 2025.